1. Medtech Insight
  2. >>Business

Interview: How Medtech Companies Are Preparing To Navigate Post-Pandemic Market

 
• By Reed Miller

In an interview with Medtech Insight, ZS consultant Brian Chapman explains how medtech companies are handling the uncertainties created by the pandemic and how it could change the industry permanently.

Recovery written on the road
• Source: shutterstock.com

Medtech companies are struggling to manage the uncertainty caused by the COVID-19 pandemic while preparing to compete in a post-pandemic market that may be significantly different than what they are accustomed to.

“The worst thing about what we’re all facing is the uncertainty,” Brian Chapman, principal with consulting firm ZS, told Medtech Insight.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.